Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity

References

• Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 2009; 31(2):184-96; PMID:19699170; http://dx.doi.org/10.1016/j.immuni.2009.08.006
   PubMed Web of Science ®Google Scholar
• Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010; 10(7):467-78; PMID:20539306; http://dx.doi.org/10.1038/nri2781
   PubMed Web of Science ®Google Scholar
• Poggi A, Zocchi MR. γδ T lymphocytes as a first line of immune defense: Old and new ways of antigen recognition and implications for cancer immunotherapy. Front Immunol 2014; 5:575; PMID:25426121; http://dx.doi.org/10.3389/fimmu.2014.00575. eCollection 2014; http://www.jem.org/cgi/doi/10.1084/jem.20021500
   PubMed Web of Science ®Google Scholar
• Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197(2):163-8; PMID:12538656; http://www.jem.org/cgi/doi/10.1084/jem.20021500
   PubMed Web of Science ®Google Scholar
• Wang H, Sarikonda G, Puan KJ, Tanaka Y, Feng J, Giner JL, Cao R, Mönkkönen J, Oldfield E, Morita CT. Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism. J Immunol 2011; 187(10):5099-113; PMID:22013129; http://dx.doi.org/10.4049/jimmunol.1002697
   PubMed Web of Science ®Google Scholar
• Kabelitz D, Kalyan S, Oberg HH, Wesch D. Human Vδ2 versus non-Vδ2 γδ T cells in anti-tumor immunity. Oncoimmunology 2013; 2(3):e23304; PMID:23802074; http://dx.doi.org/10.4161/onci.23304
   PubMed Web of Science ®Google Scholar
• Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Scotet E, Bonneville M, Jotereau F. Vgamma9 Vdelta2 T cell response to colon carcinoma cells. J Immunol 2005; 175(8):5481-8; PMID:16210656; http://doi.org/10.4049/jimmunol.175.8.5481
   PubMed Web of Science ®Google Scholar
• Bhat J, Kabelitz D. γδT cells and epigenetic drugs: A useful merger in cancer immunotherapy? Oncoimmunology 2015; 4(6):e1006088. eCollection 2015 Jun; PMID:26155411; http://dx.doi.org/10.1080/2162402X.2015.1006088
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kobayashi H, Terasaki T, Toma H, Aruga A, Uchiyama T, Mizutani K, Mikami B, Morita CT, Minato N. Synthesis of pyrophosphate-containing compounds that stimulate Vgamma2 Vdekta2 T cells: application to cancer immunotherapy. Med Chem 2007; 3(1):85-99; PMID:17266628; http://dx.doi.org/10.2174/157340607779317544
   PubMed Web of Science ®Google Scholar
• Burjanadzé M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C, Romagne F, Morel Y, Rossi JF, Klein B et al. In vitro expansion of gammadelta T cells with anti-myeloma cells activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 2007; 139(2):206-16; PMID:17897296; http://dx.doi.org/10.1111/j.1365-2141.2007.06754.x
   PubMed Web of Science ®Google Scholar
• Bennouna J, Levy V, Sicard H, Senellart H, Audrain M, Hiret S, Rolland F, Bruzzoni-Giovanelli H, Rimbert M, Galéa C et al. Phase I study of bromohydrinpyrophosphate (BrHPP, IPH 1101) a Vgamma9 Vdelta2 T lymphocyte agonist in patients with solid tumors. Cancer Immunol Immunother 2010; 59(10):1521-30; PMID:20563721; http://dx.doi.org/10.1007/s00262-010-0879-0
   PubMed Web of Science ®Google Scholar
• Capietto AH, Martinet L, Cendron D, Fruchon S, Pont F, Fournié JJ. Phophoantigens overcome human TCRVgamma9+ gammadelta T cell immunosuppression by TGF-beta: relevance for cancer immunotherapy. J Immunol 2010; 184(12):6680-7; PMID:20483742; http://dx.doi.org/10.4049/jimmunol.1000681
   PubMed Web of Science ®Google Scholar
• Russell RG. Bisphosphonates: the first 40 years. Bone 2011; 49(1):2-19; PMID:21555003; http://dx.doi.org/10.1016/j.bone.2011.04.022
   PubMed Web of Science ®Google Scholar
• Das H, Wang L, Kamath A, Bukowski JF. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001; 98(5):1616-8; PMID:11520816; http://doi.org/10.1182/blood.V98.5.1616
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasmacell activity in multiple myeloma. Blood 2000; 96(2):384-92; PMID:10887096
   PubMed Web of Science ®Google Scholar
• Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003; 102(6):2310-1; PMID:12959943; http://dx.doi.org/10.1182/blood-2003-05-1655
   PubMed Web of Science ®Google Scholar
• Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S, Tonini G. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003; 14(10):1468-76; PMID:14504045
   PubMed Web of Science ®Google Scholar
• Clézardin P, Fournier P, Boissier S, Peyruchaud O. In vitro and in vivo anti-tumor effects of bisphopshonates. Curr Med Chem 2003; 10(2):173-80; PMID:12570716; http://dx.doi.org/10.2174/0929867033368529
   PubMed Web of Science ®Google Scholar
• Märten A, Lilienfeld-Toal MV, Büchler MW, Schmidt J. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J Immunother 2007; 30(4):370-7; PMID:17457212; http://dx.doi.org/10.1097/CJI.0b013e31802bff16
   PubMed Web of Science ®Google Scholar
• Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, Orlando V, La Mendola C, Gulotta G, Salerno A et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009; 182(11):7287-96; PMID:19454726; http://dx.doi.org/10.4049/jimmunol.0804288
   PubMed Web of Science ®Google Scholar
• Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, Liu G, Eickhoff JC, McNeel DG, Malkovsky M. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother 2011; 60(10):1447-60; PMID:21647691; http://dx.doi.org/10.1007/s00262-011-1049-8
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Takamoto S, Matsushita H, Kakimi K. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδT cells: a phase I clinical study. J Immunother 2011; 34(2):202-11; PMID:21304399; http://dx.doi.org/10.1097/CJI.0b013e318207ecfb
   PubMed Web of Science ®Google Scholar
• Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010; 161(2):290-7; PMID:20491785; http://dx.doi.org/10.1111/j.1365-2249.2010.04167.x
   PubMed Web of Science ®Google Scholar
• Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N et al. Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67(15):7450-7; PMID:17671215; http://dx.doi.org/10.1158/0008-5472.CAN-07-0199
   PubMed Web of Science ®Google Scholar
• Harly C, Guillaume Y, Nedellec S, Peigné CM, Mönkkönen H, Mönkkönen J, Li J, Kuball J, Adams EJ, Netzer S et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood 2012; 120(11):2269-79; PMID:22767497; http://dx.doi.org/10.1182/blood-2012-05-430470
   PubMed Web of Science ®Google Scholar
• Palakodeti A, Sandstrom A, Sundaresan L, Harly C, Nedellec S, Olive D, Scotet E, Bonneville M, Adams EJ. The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies. J Biol Chem 2012; 287(39):32780-90; PMID:22846996; http://dx.doi.org/10.1074/jbc.M112.384354
   PubMed Web of Science ®Google Scholar
• Arnett HA, Viney JL. Immune modulation by butyrophilins. Nat Rev Immunol 2014; 14(8):559-69; PMID:25060581; http://dx.doi.org/10.1038/nri3715
   PubMed Web of Science ®Google Scholar
• Kabelitz D. Critical role of butyrophilin 3A1 in presenting prenyl pyrophosphate antigens to human γδT cells. Cell Mol Immunol 2014; 11(2):117-9; PMID:24097034; http://dx.doi.org/10.1038/cmi.2013.50
   PubMed Web of Science ®Google Scholar
• Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El Daker S, Beddoe T, Theodossis A, Williams NK, Gostick E et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat Immunol 2013; 14(9):908-16; PMID:23872678; http://dx.doi.org/10.1038/ni.2665
   PubMed Web of Science ®Google Scholar
• Wang H, Henry O, Distefano MD, Wang YC, Räikkönen J, Mönkkönen J, Tanaka Y, Morita CT. Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol 2013; 191(3):1029-42; PMID:23833237; http://dx.doi.org/10.4049/jimmunol.1300658
   PubMed Web of Science ®Google Scholar
• Sandstrom A, Peigné CM, Léger A, Crooks JE, Konczak F, Gesnel MC, Breathnach R, Bonneville M, Scotet E, Adams EJ. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. Immunity 2014; 40(4):490-500; PMID:24703779; http://dx.doi.org/10.1016/j.immuni.2014.03.003
   PubMed Web of Science ®Google Scholar
• Rhodes DA, Chen H-C, Price AJ, Keeble AH, Davey MS, James LC, Eberl M, Trowsdale J. Activation of human γδT cells by cytosolic interactions of BTN3A1 with soluble phosphoantigens and the cytoskeletal adaptor periplakin. J Immunol 2015:194(5):2390-2398; PMID:25637025; http://dx.doi.org/10.4049/Jimmunol.1401064
   PubMed Web of Science ®Google Scholar
• Sebestyen Z, Scheper W, Vyborova A, Gu S, Rychnavska Z, Schiffler M, Cleven A, Chéneau C, van Noorden M, Peigné CM et al. RhoB mediates phosphoantigen recognition by Vγ9Vδ2 T cell receptor. Cell Rep 2016; 15(9):1973-85; PMID:27210746; http://dx.doi.org/10.1016/j.celrep2016.04.081
   PubMed Web of Science ®Google Scholar
• Idrees ASM, Sugie T, Inoue C, Murata-Hirai K, Okamura H,Morita CT, Minato M, Toi M, Tanaka Y. Comparison of γδ T cell responsesand farnesyl diphosphate synthase inhibition in tunor cells pretreated with zoledronic acid. Cancer Sci 2013; 104(5):536-542; PMID:23387443; http://dx.doi.org/10.1111/cas.12124
   PubMed Web of Science ®Google Scholar
• Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, Salerno A. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J ExpMed 2003; 198(3):391-397; PMID:12900516; http://dx.doi.org/10.1084/jem.20030235
   PubMed Web of Science ®Google Scholar
• Musso A, Catellani S, Canevali P, Tavella S, Venè R, Boero S, Pierri I, Gobbi M, Kunkl A, Ravetti JL et al. Aminobisphosphonate prevent the inhibitory effect exerted by lymph node stromal cells on anti-tumor Vδ2 T lymphocytes in non-Hodgkin lymphomas. Haematologica 2014; 99(1):131-9; PMID:24162786; http://dx.doi.org/10.3324/haematol.2013.097311
   PubMed Web of Science ®Google Scholar
• Arnett HA, Escobar SS, Gonzalez-Suarez E, Budelsky AL, Steffen LA, Boiani N, Zhang M, Siu G, Brewer AW, Viney JL. BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation. J. Immunol 2007; 178(3):1523-33; PMID:17237401; http://doi.org/10.4049/jimmunol.178.3.1523
   PubMed Web of Science ®Google Scholar
• Jauhiainen M, Monkkonen H, Raikkonen J, Monkkonen J, Auriola S. Analysis of endogenous ATP analogs and mevalonate pathway mebolites in cancer cell cultures using liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877(27):2967-75; PMID:19665949; http://dx.doi.org/10.1016/j.jchromb.2009.07.010
   PubMed Web of Science ®Google Scholar
• Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas de la Pintière C, Genetet N, Meunier B, Dupont-Bierre E, Boudjema K et al. Vγ9Vδ2 T cell-mediated recognition of human solid tumor. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother 2008; 57(4):531.539; PMID:17764010; http://dx.doi.org/10.1007/s00262-007-0391-3
   PubMed Web of Science ®Google Scholar
• Musso A, Zocchi MR, Poggi A. Relevance of the mevalonate biosynthetic pathway in the regulation of bone marrow mesenchymal stromal cell-mediated effects on T-cell proliferation and B-cell survival. Haematologica 2011; 96(1):16-23; PMID:20884711; http://dx.doi.org/10.3324/haematol.2010.031633
   PubMed Web of Science ®Google Scholar
• Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B, Pantaleoni F, Foglietta M, Boccadoro M, Massaia M. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 2007; 110(3):921-7; PMID:17403919; http://dx.doi.org/10.1182/blood-2006-09-044321
   PubMed Web of Science ®Google Scholar
• Zocchi MR, Camodeca C, Nuti E, Rossello A, Venè R, Tosetti F, Dapino I, Costa D, Musso A, Poggi A. ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing. Oncoimmunol 2016; 5:5, e1123367; PMID:27467923; http://dx.doi.org/10.1080/2162402X.2015.1123367
   PubMed Web of Science ®Google Scholar